Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

7.570 +0.740 (+10.83%)
Delayed Quote Updated: 1:43 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oculis Holding AG - Ordinary shares

< Previous 1 2 3 4 Next >
Oculis Holding AG (NASDAQ:OCS) Q3 Loss Narrows as Year-End Clinical Catalysts Near ↗
Via Chartmill
News headline image
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond 
From Oculis Holding AG
Via GlobeNewswire
Oculis (NASDAQ:OCS) Beats Q2 Estimates and Advances Late-Stage Neuro-Ophthalmology Pipeline ↗
Via Chartmill
News headline image
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Resignation of Lionel Carnot from Board of Directors
From Oculis Holding AG
Via GlobeNewswire
News headline image
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough... 
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q2 2026 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.